nodes	percent_of_prediction	percent_of_DWPC	metapath
Imiquimod—CYP1A2—Pentoxifylline—systemic scleroderma	0.154	0.398	CbGbCtD
Imiquimod—CYP1A2—Leflunomide—systemic scleroderma	0.147	0.38	CbGbCtD
Imiquimod—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0477	0.123	CbGbCtD
Imiquimod—CYP3A4—Prednisone—systemic scleroderma	0.0381	0.0984	CbGbCtD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—IRF5—systemic scleroderma	0.00153	0.0954	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.0012	0.0745	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—IRF5—systemic scleroderma	0.00116	0.0723	CbGpPWpGaD
Imiquimod—TLR8—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.00113	0.0703	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.00107	0.0666	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.000906	0.0564	CbGpPWpGaD
Imiquimod—TLR7—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.000856	0.0533	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000811	0.0505	CbGpPWpGaD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.000452	0.0282	CbGpPWpGaD
Imiquimod—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000372	0.000623	CcSEcCtD
Imiquimod—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000371	0.000622	CcSEcCtD
Imiquimod—Diarrhoea—Captopril—systemic scleroderma	0.000371	0.000621	CcSEcCtD
Imiquimod—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00037	0.000621	CcSEcCtD
Imiquimod—Irritability—Methotrexate—systemic scleroderma	0.00037	0.00062	CcSEcCtD
Imiquimod—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000369	0.000619	CcSEcCtD
Imiquimod—Erectile dysfunction—Prednisone—systemic scleroderma	0.000369	0.000619	CcSEcCtD
Imiquimod—Feeling abnormal—Leflunomide—systemic scleroderma	0.000368	0.000617	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000368	0.000617	CcSEcCtD
Imiquimod—Fatigue—Mycophenolic acid—systemic scleroderma	0.000367	0.000616	CcSEcCtD
Imiquimod—Nausea—Mometasone—systemic scleroderma	0.000367	0.000614	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—ITGAM—systemic scleroderma	0.000366	0.0228	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—CD247—systemic scleroderma	0.000366	0.0228	CbGpPWpGaD
Imiquimod—Anorexia—Lisinopril—systemic scleroderma	0.000366	0.000613	CcSEcCtD
Imiquimod—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000365	0.000612	CcSEcCtD
Imiquimod—Pain—Mycophenolic acid—systemic scleroderma	0.000364	0.000611	CcSEcCtD
Imiquimod—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000364	0.00061	CcSEcCtD
Imiquimod—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000362	0.000607	CcSEcCtD
Imiquimod—Cough—Mycophenolate mofetil—systemic scleroderma	0.00036	0.000603	CcSEcCtD
Imiquimod—Dizziness—Captopril—systemic scleroderma	0.000358	0.000601	CcSEcCtD
Imiquimod—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000357	0.000598	CcSEcCtD
Imiquimod—Depression—Prednisone—systemic scleroderma	0.000356	0.000597	CcSEcCtD
Imiquimod—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000356	0.000596	CcSEcCtD
Imiquimod—Urticaria—Leflunomide—systemic scleroderma	0.000355	0.000595	CcSEcCtD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000353	0.022	CbGpPWpGaD
Imiquimod—Abdominal pain—Leflunomide—systemic scleroderma	0.000353	0.000592	CcSEcCtD
Imiquimod—Body temperature increased—Leflunomide—systemic scleroderma	0.000353	0.000592	CcSEcCtD
Imiquimod—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000352	0.00059	CcSEcCtD
Imiquimod—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000351	0.000589	CcSEcCtD
Imiquimod—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000351	0.000588	CcSEcCtD
Imiquimod—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000351	0.000588	CcSEcCtD
Imiquimod—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000351	0.000588	CcSEcCtD
Imiquimod—Myocardial infarction—Prednisone—systemic scleroderma	0.00035	0.000587	CcSEcCtD
Imiquimod—Neuropathy peripheral—Prednisone—systemic scleroderma	0.00035	0.000587	CcSEcCtD
Imiquimod—Breast disorder—Methotrexate—systemic scleroderma	0.00035	0.000587	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00035	0.000586	CcSEcCtD
Imiquimod—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.00035	0.000586	CcSEcCtD
Imiquimod—Hypersensitivity—Azathioprine—systemic scleroderma	0.000348	0.000584	CcSEcCtD
Imiquimod—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000348	0.000584	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000348	0.000584	CcSEcCtD
Imiquimod—Insomnia—Lisinopril—systemic scleroderma	0.000347	0.000582	CcSEcCtD
Imiquimod—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000347	0.000581	CcSEcCtD
Imiquimod—Paraesthesia—Lisinopril—systemic scleroderma	0.000345	0.000578	CcSEcCtD
Imiquimod—Vomiting—Captopril—systemic scleroderma	0.000345	0.000578	CcSEcCtD
Imiquimod—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000343	0.000575	CcSEcCtD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.000343	0.0214	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—TNFAIP3—systemic scleroderma	0.000343	0.0213	CbGpPWpGaD
Imiquimod—Dyspnoea—Lisinopril—systemic scleroderma	0.000342	0.000573	CcSEcCtD
Imiquimod—Rash—Captopril—systemic scleroderma	0.000342	0.000573	CcSEcCtD
Imiquimod—Dermatitis—Captopril—systemic scleroderma	0.000341	0.000572	CcSEcCtD
Imiquimod—Somnolence—Lisinopril—systemic scleroderma	0.000341	0.000572	CcSEcCtD
Imiquimod—Headache—Captopril—systemic scleroderma	0.00034	0.000569	CcSEcCtD
Imiquimod—Dyspepsia—Lisinopril—systemic scleroderma	0.000338	0.000566	CcSEcCtD
Imiquimod—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000337	0.000565	CcSEcCtD
Imiquimod—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000337	0.000565	CcSEcCtD
Imiquimod—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000336	0.000564	CcSEcCtD
Imiquimod—Infection—Mycophenolate mofetil—systemic scleroderma	0.000334	0.00056	CcSEcCtD
Imiquimod—Decreased appetite—Lisinopril—systemic scleroderma	0.000334	0.000559	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000331	0.000555	CcSEcCtD
Imiquimod—Fatigue—Lisinopril—systemic scleroderma	0.000331	0.000555	CcSEcCtD
Imiquimod—Shock—Mycophenolate mofetil—systemic scleroderma	0.000331	0.000554	CcSEcCtD
Imiquimod—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00033	0.000553	CcSEcCtD
Imiquimod—Hypersensitivity—Leflunomide—systemic scleroderma	0.000329	0.000552	CcSEcCtD
Imiquimod—Pain—Lisinopril—systemic scleroderma	0.000328	0.00055	CcSEcCtD
Imiquimod—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000328	0.00055	CcSEcCtD
Imiquimod—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000327	0.000547	CcSEcCtD
Imiquimod—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000325	0.000545	CcSEcCtD
Imiquimod—Diarrhoea—Azathioprine—systemic scleroderma	0.000324	0.000542	CcSEcCtD
Imiquimod—Haemoglobin—Prednisone—systemic scleroderma	0.000322	0.00054	CcSEcCtD
Imiquimod—Nausea—Captopril—systemic scleroderma	0.000322	0.00054	CcSEcCtD
Imiquimod—Haemorrhage—Prednisone—systemic scleroderma	0.000321	0.000538	CcSEcCtD
Imiquimod—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000321	0.000537	CcSEcCtD
Imiquimod—Asthenia—Leflunomide—systemic scleroderma	0.00032	0.000537	CcSEcCtD
Imiquimod—Pancytopenia—Methotrexate—systemic scleroderma	0.000318	0.000533	CcSEcCtD
Imiquimod—Feeling abnormal—Lisinopril—systemic scleroderma	0.000316	0.00053	CcSEcCtD
Imiquimod—Pruritus—Leflunomide—systemic scleroderma	0.000316	0.00053	CcSEcCtD
Imiquimod—Connective tissue disorder—Prednisone—systemic scleroderma	0.000315	0.000528	CcSEcCtD
Imiquimod—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000314	0.000526	CcSEcCtD
Imiquimod—Dysuria—Methotrexate—systemic scleroderma	0.000313	0.000525	CcSEcCtD
Imiquimod—Dizziness—Azathioprine—systemic scleroderma	0.000313	0.000524	CcSEcCtD
Imiquimod—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000311	0.000522	CcSEcCtD
Imiquimod—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000309	0.000517	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000306	0.000513	CcSEcCtD
Imiquimod—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000306	0.000512	CcSEcCtD
Imiquimod—Asthenia—Mycophenolic acid—systemic scleroderma	0.000306	0.000512	CcSEcCtD
Imiquimod—Diarrhoea—Leflunomide—systemic scleroderma	0.000306	0.000512	CcSEcCtD
Imiquimod—Urticaria—Lisinopril—systemic scleroderma	0.000305	0.000511	CcSEcCtD
Imiquimod—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000304	0.00051	CcSEcCtD
Imiquimod—Body temperature increased—Lisinopril—systemic scleroderma	0.000303	0.000509	CcSEcCtD
Imiquimod—Abdominal pain—Lisinopril—systemic scleroderma	0.000303	0.000509	CcSEcCtD
Imiquimod—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000302	0.000506	CcSEcCtD
Imiquimod—Pruritus—Mycophenolic acid—systemic scleroderma	0.000301	0.000505	CcSEcCtD
Imiquimod—Vomiting—Azathioprine—systemic scleroderma	0.000301	0.000504	CcSEcCtD
Imiquimod—Eye disorder—Prednisone—systemic scleroderma	0.0003	0.000503	CcSEcCtD
Imiquimod—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.0003	0.000502	CcSEcCtD
Imiquimod—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000299	0.000501	CcSEcCtD
Imiquimod—Infestation—Methotrexate—systemic scleroderma	0.000299	0.000501	CcSEcCtD
Imiquimod—Infestation NOS—Methotrexate—systemic scleroderma	0.000299	0.000501	CcSEcCtD
Imiquimod—Rash—Azathioprine—systemic scleroderma	0.000298	0.0005	CcSEcCtD
Imiquimod—Dermatitis—Azathioprine—systemic scleroderma	0.000298	0.000499	CcSEcCtD
Imiquimod—Depression—Methotrexate—systemic scleroderma	0.000298	0.000499	CcSEcCtD
Imiquimod—Flushing—Prednisone—systemic scleroderma	0.000298	0.000499	CcSEcCtD
Imiquimod—Headache—Azathioprine—systemic scleroderma	0.000296	0.000497	CcSEcCtD
Imiquimod—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000296	0.000496	CcSEcCtD
Imiquimod—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000296	0.000496	CcSEcCtD
Imiquimod—Dizziness—Leflunomide—systemic scleroderma	0.000295	0.000495	CcSEcCtD
Imiquimod—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000292	0.00049	CcSEcCtD
Imiquimod—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000292	0.000489	CcSEcCtD
Imiquimod—Angiopathy—Prednisone—systemic scleroderma	0.000291	0.000488	CcSEcCtD
Imiquimod—Conjunctivitis—Methotrexate—systemic scleroderma	0.00029	0.000487	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00029	0.000487	CcSEcCtD
Imiquimod—Immune system disorder—Prednisone—systemic scleroderma	0.00029	0.000486	CcSEcCtD
Imiquimod—Pain—Mycophenolate mofetil—systemic scleroderma	0.000288	0.000482	CcSEcCtD
Imiquimod—Arrhythmia—Prednisone—systemic scleroderma	0.000287	0.00048	CcSEcCtD
Imiquimod—Vomiting—Leflunomide—systemic scleroderma	0.000284	0.000476	CcSEcCtD
Imiquimod—Alopecia—Prednisone—systemic scleroderma	0.000284	0.000475	CcSEcCtD
Imiquimod—Hypersensitivity—Lisinopril—systemic scleroderma	0.000283	0.000474	CcSEcCtD
Imiquimod—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000282	0.000473	CcSEcCtD
Imiquimod—Dizziness—Mycophenolic acid—systemic scleroderma	0.000282	0.000472	CcSEcCtD
Imiquimod—Rash—Leflunomide—systemic scleroderma	0.000282	0.000472	CcSEcCtD
Imiquimod—Dermatitis—Leflunomide—systemic scleroderma	0.000281	0.000472	CcSEcCtD
Imiquimod—Mental disorder—Prednisone—systemic scleroderma	0.000281	0.000471	CcSEcCtD
Imiquimod—Nausea—Azathioprine—systemic scleroderma	0.000281	0.000471	CcSEcCtD
Imiquimod—Headache—Leflunomide—systemic scleroderma	0.00028	0.000469	CcSEcCtD
Imiquimod—Malnutrition—Prednisone—systemic scleroderma	0.000279	0.000468	CcSEcCtD
Imiquimod—Erythema—Prednisone—systemic scleroderma	0.000279	0.000468	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—ITGAM—systemic scleroderma	0.000277	0.0173	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CD247—systemic scleroderma	0.000277	0.0173	CbGpPWpGaD
Imiquimod—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000277	0.000464	CcSEcCtD
Imiquimod—Asthenia—Lisinopril—systemic scleroderma	0.000275	0.000462	CcSEcCtD
Imiquimod—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000275	0.000461	CcSEcCtD
Imiquimod—Pruritus—Lisinopril—systemic scleroderma	0.000272	0.000455	CcSEcCtD
Imiquimod—Vomiting—Mycophenolic acid—systemic scleroderma	0.000271	0.000454	CcSEcCtD
Imiquimod—Haemoglobin—Methotrexate—systemic scleroderma	0.000269	0.000452	CcSEcCtD
Imiquimod—Rash—Mycophenolic acid—systemic scleroderma	0.000269	0.00045	CcSEcCtD
Imiquimod—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000268	0.00045	CcSEcCtD
Imiquimod—Haemorrhage—Methotrexate—systemic scleroderma	0.000268	0.000449	CcSEcCtD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000268	0.0167	CbGpPWpGaD
Imiquimod—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000267	0.000448	CcSEcCtD
Imiquimod—Headache—Mycophenolic acid—systemic scleroderma	0.000267	0.000447	CcSEcCtD
Imiquimod—Pharyngitis—Methotrexate—systemic scleroderma	0.000266	0.000446	CcSEcCtD
Imiquimod—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000266	0.000446	CcSEcCtD
Imiquimod—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000266	0.000446	CcSEcCtD
Imiquimod—Nausea—Leflunomide—systemic scleroderma	0.000265	0.000445	CcSEcCtD
Imiquimod—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000265	0.000444	CcSEcCtD
Imiquimod—Urethral disorder—Methotrexate—systemic scleroderma	0.000263	0.000441	CcSEcCtD
Imiquimod—Diarrhoea—Lisinopril—systemic scleroderma	0.000263	0.00044	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—TNFAIP3—systemic scleroderma	0.00026	0.0162	CbGpPWpGaD
Imiquimod—Ill-defined disorder—Prednisone—systemic scleroderma	0.000259	0.000434	CcSEcCtD
Imiquimod—Visual impairment—Methotrexate—systemic scleroderma	0.000258	0.000433	CcSEcCtD
Imiquimod—Agitation—Prednisone—systemic scleroderma	0.000257	0.00043	CcSEcCtD
Imiquimod—Angioedema—Prednisone—systemic scleroderma	0.000255	0.000428	CcSEcCtD
Imiquimod—Dizziness—Lisinopril—systemic scleroderma	0.000254	0.000425	CcSEcCtD
Imiquimod—Erythema multiforme—Methotrexate—systemic scleroderma	0.000254	0.000425	CcSEcCtD
Imiquimod—Nausea—Mycophenolic acid—systemic scleroderma	0.000253	0.000424	CcSEcCtD
Imiquimod—Malaise—Prednisone—systemic scleroderma	0.000252	0.000422	CcSEcCtD
Imiquimod—Eye disorder—Methotrexate—systemic scleroderma	0.000251	0.00042	CcSEcCtD
Imiquimod—Syncope—Prednisone—systemic scleroderma	0.00025	0.00042	CcSEcCtD
Imiquimod—Tinnitus—Methotrexate—systemic scleroderma	0.00025	0.000419	CcSEcCtD
Imiquimod—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000248	0.000415	CcSEcCtD
Imiquimod—Loss of consciousness—Prednisone—systemic scleroderma	0.000245	0.000411	CcSEcCtD
Imiquimod—Vomiting—Lisinopril—systemic scleroderma	0.000244	0.000409	CcSEcCtD
Imiquimod—Angiopathy—Methotrexate—systemic scleroderma	0.000243	0.000408	CcSEcCtD
Imiquimod—Immune system disorder—Methotrexate—systemic scleroderma	0.000242	0.000406	CcSEcCtD
Imiquimod—Rash—Lisinopril—systemic scleroderma	0.000242	0.000406	CcSEcCtD
Imiquimod—Convulsion—Prednisone—systemic scleroderma	0.000242	0.000406	CcSEcCtD
Imiquimod—Dermatitis—Lisinopril—systemic scleroderma	0.000242	0.000405	CcSEcCtD
Imiquimod—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000242	0.000405	CcSEcCtD
Imiquimod—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000241	0.000404	CcSEcCtD
Imiquimod—Hypertension—Prednisone—systemic scleroderma	0.000241	0.000404	CcSEcCtD
Imiquimod—Chills—Methotrexate—systemic scleroderma	0.000241	0.000403	CcSEcCtD
Imiquimod—Headache—Lisinopril—systemic scleroderma	0.00024	0.000403	CcSEcCtD
Imiquimod—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000238	0.000399	CcSEcCtD
Imiquimod—Myalgia—Prednisone—systemic scleroderma	0.000238	0.000399	CcSEcCtD
Imiquimod—Arthralgia—Prednisone—systemic scleroderma	0.000238	0.000399	CcSEcCtD
Imiquimod—Anxiety—Prednisone—systemic scleroderma	0.000237	0.000397	CcSEcCtD
Imiquimod—Alopecia—Methotrexate—systemic scleroderma	0.000237	0.000397	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000236	0.000396	CcSEcCtD
Imiquimod—Discomfort—Prednisone—systemic scleroderma	0.000235	0.000394	CcSEcCtD
Imiquimod—Mental disorder—Methotrexate—systemic scleroderma	0.000235	0.000394	CcSEcCtD
Imiquimod—Erythema—Methotrexate—systemic scleroderma	0.000233	0.000391	CcSEcCtD
Imiquimod—Malnutrition—Methotrexate—systemic scleroderma	0.000233	0.000391	CcSEcCtD
Imiquimod—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00023	0.000386	CcSEcCtD
Imiquimod—Nausea—Lisinopril—systemic scleroderma	0.000228	0.000382	CcSEcCtD
Imiquimod—Oedema—Prednisone—systemic scleroderma	0.000228	0.000382	CcSEcCtD
Imiquimod—TLR8—Immune System—CSK—systemic scleroderma	0.000227	0.0141	CbGpPWpGaD
Imiquimod—Infection—Prednisone—systemic scleroderma	0.000226	0.00038	CcSEcCtD
Imiquimod—Back pain—Methotrexate—systemic scleroderma	0.000226	0.000378	CcSEcCtD
Imiquimod—Shock—Prednisone—systemic scleroderma	0.000224	0.000376	CcSEcCtD
Imiquimod—Nervous system disorder—Prednisone—systemic scleroderma	0.000224	0.000375	CcSEcCtD
Imiquimod—TLR8—Immune System—IRF5—systemic scleroderma	0.000223	0.0139	CbGpPWpGaD
Imiquimod—Tachycardia—Prednisone—systemic scleroderma	0.000222	0.000373	CcSEcCtD
Imiquimod—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000222	0.000373	CcSEcCtD
Imiquimod—Skin disorder—Prednisone—systemic scleroderma	0.000221	0.000371	CcSEcCtD
Imiquimod—Hyperhidrosis—Prednisone—systemic scleroderma	0.00022	0.000369	CcSEcCtD
Imiquimod—Anorexia—Prednisone—systemic scleroderma	0.000217	0.000364	CcSEcCtD
Imiquimod—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000217	0.000363	CcSEcCtD
Imiquimod—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000214	0.000358	CcSEcCtD
Imiquimod—TLR8—Immune System—ITGAM—systemic scleroderma	0.000213	0.0133	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IRF8—systemic scleroderma	0.000213	0.0133	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CD247—systemic scleroderma	0.000213	0.0133	CbGpPWpGaD
Imiquimod—Rash—Mycophenolate mofetil—systemic scleroderma	0.000212	0.000355	CcSEcCtD
Imiquimod—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000212	0.000355	CcSEcCtD
Imiquimod—Headache—Mycophenolate mofetil—systemic scleroderma	0.000211	0.000353	CcSEcCtD
Imiquimod—Malaise—Methotrexate—systemic scleroderma	0.00021	0.000353	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000208	0.000348	CcSEcCtD
Imiquimod—Insomnia—Prednisone—systemic scleroderma	0.000206	0.000346	CcSEcCtD
Imiquimod—Paraesthesia—Prednisone—systemic scleroderma	0.000205	0.000343	CcSEcCtD
Imiquimod—Cough—Methotrexate—systemic scleroderma	0.000204	0.000341	CcSEcCtD
Imiquimod—Convulsion—Methotrexate—systemic scleroderma	0.000202	0.000339	CcSEcCtD
Imiquimod—Dyspepsia—Prednisone—systemic scleroderma	0.000201	0.000336	CcSEcCtD
Imiquimod—Nausea—Mycophenolate mofetil—systemic scleroderma	0.0002	0.000335	CcSEcCtD
Imiquimod—TLR8—Immune System—TNFAIP3—systemic scleroderma	0.0002	0.0124	CbGpPWpGaD
Imiquimod—Chest pain—Methotrexate—systemic scleroderma	0.000199	0.000333	CcSEcCtD
Imiquimod—Arthralgia—Methotrexate—systemic scleroderma	0.000199	0.000333	CcSEcCtD
Imiquimod—Myalgia—Methotrexate—systemic scleroderma	0.000199	0.000333	CcSEcCtD
Imiquimod—Decreased appetite—Prednisone—systemic scleroderma	0.000198	0.000332	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000197	0.000331	CcSEcCtD
Imiquimod—TLR8—Immune System—BLK—systemic scleroderma	0.000197	0.0123	CbGpPWpGaD
Imiquimod—Fatigue—Prednisone—systemic scleroderma	0.000197	0.000329	CcSEcCtD
Imiquimod—Discomfort—Methotrexate—systemic scleroderma	0.000196	0.000329	CcSEcCtD
Imiquimod—Infection—Methotrexate—systemic scleroderma	0.000189	0.000317	CcSEcCtD
Imiquimod—Feeling abnormal—Prednisone—systemic scleroderma	0.000188	0.000315	CcSEcCtD
Imiquimod—Nervous system disorder—Methotrexate—systemic scleroderma	0.000187	0.000313	CcSEcCtD
Imiquimod—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000186	0.000312	CcSEcCtD
Imiquimod—Skin disorder—Methotrexate—systemic scleroderma	0.000185	0.00031	CcSEcCtD
Imiquimod—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000184	0.000309	CcSEcCtD
Imiquimod—CYP1A2—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000182	0.0113	CbGpPWpGaD
Imiquimod—Anorexia—Methotrexate—systemic scleroderma	0.000182	0.000304	CcSEcCtD
Imiquimod—Urticaria—Prednisone—systemic scleroderma	0.000181	0.000303	CcSEcCtD
Imiquimod—Abdominal pain—Prednisone—systemic scleroderma	0.00018	0.000302	CcSEcCtD
Imiquimod—Body temperature increased—Prednisone—systemic scleroderma	0.00018	0.000302	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000174	0.000291	CcSEcCtD
Imiquimod—Insomnia—Methotrexate—systemic scleroderma	0.000172	0.000289	CcSEcCtD
Imiquimod—TLR7—Immune System—CSK—systemic scleroderma	0.000172	0.0107	CbGpPWpGaD
Imiquimod—Paraesthesia—Methotrexate—systemic scleroderma	0.000171	0.000287	CcSEcCtD
Imiquimod—Dyspnoea—Methotrexate—systemic scleroderma	0.00017	0.000285	CcSEcCtD
Imiquimod—Somnolence—Methotrexate—systemic scleroderma	0.000169	0.000284	CcSEcCtD
Imiquimod—TLR7—Immune System—IRF5—systemic scleroderma	0.000169	0.0105	CbGpPWpGaD
Imiquimod—Hypersensitivity—Prednisone—systemic scleroderma	0.000168	0.000281	CcSEcCtD
Imiquimod—Dyspepsia—Methotrexate—systemic scleroderma	0.000168	0.000281	CcSEcCtD
Imiquimod—Decreased appetite—Methotrexate—systemic scleroderma	0.000166	0.000278	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000164	0.000276	CcSEcCtD
Imiquimod—Fatigue—Methotrexate—systemic scleroderma	0.000164	0.000275	CcSEcCtD
Imiquimod—Asthenia—Prednisone—systemic scleroderma	0.000164	0.000274	CcSEcCtD
Imiquimod—Pain—Methotrexate—systemic scleroderma	0.000163	0.000273	CcSEcCtD
Imiquimod—TLR7—Immune System—ITGAM—systemic scleroderma	0.000162	0.0101	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IRF8—systemic scleroderma	0.000162	0.0101	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CTLA4—systemic scleroderma	0.000162	0.0101	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD247—systemic scleroderma	0.000162	0.0101	CbGpPWpGaD
Imiquimod—Pruritus—Prednisone—systemic scleroderma	0.000161	0.00027	CcSEcCtD
Imiquimod—Feeling abnormal—Methotrexate—systemic scleroderma	0.000157	0.000263	CcSEcCtD
Imiquimod—Diarrhoea—Prednisone—systemic scleroderma	0.000156	0.000261	CcSEcCtD
Imiquimod—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000156	0.000261	CcSEcCtD
Imiquimod—Urticaria—Methotrexate—systemic scleroderma	0.000151	0.000254	CcSEcCtD
Imiquimod—TLR7—Immune System—TNFAIP3—systemic scleroderma	0.000151	0.00942	CbGpPWpGaD
Imiquimod—Dizziness—Prednisone—systemic scleroderma	0.000151	0.000253	CcSEcCtD
Imiquimod—Abdominal pain—Methotrexate—systemic scleroderma	0.000151	0.000252	CcSEcCtD
Imiquimod—Body temperature increased—Methotrexate—systemic scleroderma	0.000151	0.000252	CcSEcCtD
Imiquimod—TLR7—Immune System—BLK—systemic scleroderma	0.000149	0.00931	CbGpPWpGaD
Imiquimod—Vomiting—Prednisone—systemic scleroderma	0.000145	0.000243	CcSEcCtD
Imiquimod—Rash—Prednisone—systemic scleroderma	0.000144	0.000241	CcSEcCtD
Imiquimod—Dermatitis—Prednisone—systemic scleroderma	0.000144	0.000241	CcSEcCtD
Imiquimod—Headache—Prednisone—systemic scleroderma	0.000143	0.000239	CcSEcCtD
Imiquimod—Hypersensitivity—Methotrexate—systemic scleroderma	0.00014	0.000235	CcSEcCtD
Imiquimod—Asthenia—Methotrexate—systemic scleroderma	0.000137	0.000229	CcSEcCtD
Imiquimod—Nausea—Prednisone—systemic scleroderma	0.000135	0.000227	CcSEcCtD
Imiquimod—Pruritus—Methotrexate—systemic scleroderma	0.000135	0.000226	CcSEcCtD
Imiquimod—TLR8—Immune System—HLA-DQB1—systemic scleroderma	0.000133	0.00828	CbGpPWpGaD
Imiquimod—Diarrhoea—Methotrexate—systemic scleroderma	0.00013	0.000218	CcSEcCtD
Imiquimod—TLR8—Immune System—IL1A—systemic scleroderma	0.000126	0.00787	CbGpPWpGaD
Imiquimod—Dizziness—Methotrexate—systemic scleroderma	0.000126	0.000211	CcSEcCtD
Imiquimod—TLR8—Immune System—CD40LG—systemic scleroderma	0.000126	0.00782	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CTLA4—systemic scleroderma	0.000122	0.00762	CbGpPWpGaD
Imiquimod—Vomiting—Methotrexate—systemic scleroderma	0.000121	0.000203	CcSEcCtD
Imiquimod—Rash—Methotrexate—systemic scleroderma	0.00012	0.000201	CcSEcCtD
Imiquimod—Dermatitis—Methotrexate—systemic scleroderma	0.00012	0.000201	CcSEcCtD
Imiquimod—Headache—Methotrexate—systemic scleroderma	0.000119	0.0002	CcSEcCtD
Imiquimod—Nausea—Methotrexate—systemic scleroderma	0.000113	0.00019	CcSEcCtD
Imiquimod—TLR7—Immune System—HLA-DQB1—systemic scleroderma	0.000101	0.00628	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IL1A—systemic scleroderma	9.58e-05	0.00596	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD40LG—systemic scleroderma	9.52e-05	0.00593	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IL1B—systemic scleroderma	6.59e-05	0.0041	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	6.53e-05	0.00407	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	5.08e-05	0.00316	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IL1B—systemic scleroderma	4.99e-05	0.00311	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.11e-05	0.00194	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.36e-05	0.00147	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—HSPG2—systemic scleroderma	1.39e-05	0.000863	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.07e-05	0.000666	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CTGF—systemic scleroderma	1.05e-05	0.000654	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CTGF—systemic scleroderma	8.1e-06	0.000505	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—NOS3—systemic scleroderma	4.57e-06	0.000285	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—NOS3—systemic scleroderma	3.53e-06	0.00022	CbGpPWpGaD
